CING insider transaction filings
Cingulate Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-20. Screen CING transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Silva Raul R. — EVP and CSO | 2 | — | — | 3 |
| Brams Matthew — EVP and Chief Medical Officer | 1 | — | — | 2 |
| Callahan Jennifer L. — EVP and CFO | 1 | — | — | 2 |
| Downey Bryan Wade — EVP & Chief Commercial Officer | 1 | — | — | 2 |
| Schaffer Shane J. — Chief Executive Officer, Director | 1 | — | — | 2 |
| Hargroves Thomas Jeffrey — Director | 1 | — | — | 1 |
| Lawrence Bryan Jay — Director | 1 | — | — | 1 |
| Werth Peter J. — Director | 1 | — | — | 1 |
Recent Form 4 filings — Cingulate Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-20 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Grant/award (A): 197,650 (derivative) @ $0 · Grant/award (A): 97,350 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Downey Bryan Wade — EVP & Chief Commercial Officer | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Lawrence Bryan Jay — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 53,600 (derivative) @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Hargroves Thomas Jeffrey — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Callahan Jennifer L. — EVP and CFO | Grant/award (A): 40,200 (derivative) @ $0 · Grant/award (A): 19,800 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Werth Peter J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 53,600 (derivative) @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 3,885 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Hargroves Thomas Jeffrey — Director | Purchase (P): 97,276 @ $5.04 · Purchase (P): 77,821 (derivative) @ $0.10 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 3,422 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 4,526 @ $0 · Tax withholding (F): 1,828 @ $0 | EDGAR |
| 2026-03-11 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Grant/award (A): 6,862 @ $0 · Tax withholding (F): 2,959 @ $0 | EDGAR |
| 2026-03-11 | 4 | Patel Nilay Dahyabhai — EVP, CLO and CCO | Grant/award (A): 5,475 @ $0 · Tax withholding (F): 2,086 @ $0 | EDGAR |
| 2026-03-11 | 4 | Callahan Jennifer L. — EVP and CFO | Grant/award (A): 15,329 @ $0 · Tax withholding (F): 6,427 @ $0 | EDGAR |
| 2026-03-11 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 4,526 @ $0 · Tax withholding (F): 1,025 @ $0 | EDGAR |
| 2026-02-10 | 4 | Werth Peter J. — Director | Purchase (P): 19,455 @ $5.04 · Purchase (P): 15,564 (derivative) @ $0.10 | EDGAR |
| 2026-02-10 | 4 | Callahan Jennifer L. — SVP and CFO | Purchase (P): 4,864 @ $5.04 · Purchase (P): 3,891 (derivative) @ $0.10 | EDGAR |
| 2026-02-10 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Purchase (P): 6,809 @ $5.04 · Purchase (P): 5,447 (derivative) @ $0.10 | EDGAR |
| 2026-02-10 | 4 | Brams Matthew — EVP and Chief Medical Officer | Purchase (P): 1,946 @ $5.04 · Purchase (P): 1,556 (derivative) @ $0.10 | EDGAR |
| 2026-01-05 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 6,625 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 7,334 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | Downey Bryan Wade — Chief Commercial Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Patel Nilay Dahyabhai — CLO and CCO | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 51,500 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Grant/award (A): 199,500 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Myers Laurie — EVP and COO | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Callahan Jennifer L. — SVP and CFO | Grant/award (A): 64,500 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 52,500 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 1,000 (derivative) @ $0 · Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Werth Peter J. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Lawrence Bryan Jay — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Ervin Jeffrey S — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | ROBERTS JOHN A — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Callahan Jennifer L. — SVP and CFO | Grant/award (A): 21,140 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Grant/award (A): 70,489 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Myers Laurie — EVP and COO | Grant/award (A): 17,630 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 17,630 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 17,630 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Callahan Jennifer L. — SVP and CFO | Grant/award (A): 11,539 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 2,748 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Myers Laurie — EVP and COO | Grant/award (A): 9,319 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Schaffer Shane J. — Chief Executive Officer, Director | Grant/award (A): 27,638 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 2,748 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Silva Raul R. — EVP and CSO | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-08-19 | 4 | Myers Laurie — EVP and COO | Sale (S): 202 @ $4.17 | EDGAR |
| 2024-07-02 | 4 | Brams Matthew — EVP and Chief Medical Officer | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cingulate Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CING returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →